Health & Fitness
Health and Fitness
Health and Fitness
Thu, August 19, 2010
Wed, August 18, 2010
Tue, August 17, 2010
Elan, Transition Therapeutics, Pfizer, Novartis AG, Johnson & Johnson and Forest Laboratories
CHICAGO--([ BUSINESS WIRE ])--Zacks.com Analyst Blog features: Elan Corporation Plc. (NYSE: [ ELN ]), Transition Therapeutics Inc. (Nasdaq: [ TTHI ]), Pfizer Inc. (NYSE: [ PFE ]), Novartis AG (NYSE: [ NVS ]), Johnson & Johnson (NYSE: [ JNJ ]) and Forest Laboratories, Inc. (NYSE: [ FRX ]).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=4579 ]
Here are highlights from Mondaya™s Analyst Blog:
Elan to Move ELND005 to Phase III
Elan Corporation Plc. (NYSE: [ ELN ]) and partner Transition Therapeutics Inc. (Nasdaq: [ TTHI ]) recently announced their plans to move their Alzheimera™s disease pipeline candidate ELND005 into late stage trails. The companies also reported data from a mid-stage trial on ELND005. The companies presented positive safety and tolerability data on ELND005 taken twice-daily, for about 18 months. However, the triala™s cognitive and functional co-primary endpoints failed to achieve statistical significance.
The trial (AD201) initially enrolled 351 patients with mild-to-moderate Alzheimera™s disease at about 65 sites in the US. The study included four treatment arms: placebo, 250 mg BID, 1000 mg BID and 2000 mg BID. The 1000 mg BID and 2000 mg BID trials were discontinued in December last year due to serious adverse events, including mortality.
Based on these results, Elan and Transition Therapeutics plan to move ELND005 into phase III trials, the details of which are not currently available. We believe the companies will seek to enter into a partnership deal before commencing phase III studies. The signing of a lucrative deal would bring in additional funds, which would help finance the advanced stage development of the candidate.
Potential for ELND005
ELND005 received fast track designation from the US Food and Drug Administration (FDA) in 2007 for the treatment of Alzheimer's disease. According to the Alzheimer's Association and Alzheimer's Disease International, more than five million Americans have Alzheimer's disease while more than 26 million people worldwide suffer from some form of dementia.
The Alzheimer's disease market consists of players like Pfizer Inc. (NYSE: [ PFE ]), Novartis AG (NYSE: [ NVS ]), Johnson & Johnson (NYSE: [ JNJ ]) and Forest Laboratories, Inc. (NYSE: [ FRX ]). It is estimated that the market is currently worth more than $5 billion.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=5514 ].
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: [ http://at.zacks.com/?id=5516 ]
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4580 ].
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Follow us on Twitter: [ http://twitter.com/zacksresearch ]
Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
